US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Respiratory/Pulmonary Market Research Reports & Industry Analysis

RSS Feeds

Respiratory/Pulmonary Industry Research & Market Reports

1    3    5  6  7  8  9  10  
Pulmonary Hypertension - Pipeline Review, H2 2014
7/31/2014 | published by: Global Markets Direct
... therapeutic development for Pulmonary Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ...  |  read more...
USD 2,000
Physician Views: How do pulmonologists value medical affairs teams – what could they be doing better?
7/9/2014 | published by: FirstWord
... efficient workings of healthcare systems. Not only do medical affairs personnel sit at an interface between the R&D and commercial spheres, but represent the voice of the company in communication with a growing range of ...  |  read more...
USD 645
Chronic Bronchitis - Pipeline Review, H2 2014
7/31/2014 | published by: Global Markets Direct
... therapeutic development for Chronic Bronchitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ...  |  read more...
USD 2,000
Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2014
7/31/2014 | published by: Global Markets Direct
... therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Respiratory Syncytial Virus (RSV) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of ...  |  read more...
USD 2,000
Idiopathic pulmonary fibrosis – on the cusp of a revolution; how will forthcoming approvals shape the treatment and development landscapes? - Physician Views
5/27/2014 | published by: FirstWord
... pulmonary fibrosis (IPF). Positive Phase III data are expected to act as the springboard for FDA approvals of InterMune's Esbriet (pirfenidone) and Boehringer Ingelheim's nintedanib by late 2014/early 2015. Launch and uptake of these products ...  |  read more...
USD 645
Cough Drugs Markets in China
6/1/2014 | published by: Asia Market Information & Development Company
... new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2003, 2008 and 2013) and long-term forecasts through 2018 and ...  |  read more...
USD 4,000
Lung Cancer Treatment Drugs Markets in China
6/1/2014 | published by: Asia Market Information & Development Company
... continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2003, 2008 and 2013) and long-term ...  |  read more...
USD 4,000
Squamous Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014
5/26/2014 | published by: GlobalData
... Lung Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Squamous Non-Small Cell Lung Cancer. It includes an overview of the trial numbers and their recruitment status ...  |  read more...
USD 2,500
Market Highlights: US Chronic Obstructive Pulmonary Disease – 2014
5/1/2014 | published by: Fore Pharma
... obstructive pulmonary disease drug sales forecast in the US. The research includes the US chronic obstructive pulmonary disease market size estimates for 2013, market share forecast for six years to 2019, chronic obstructive pulmonary disease ...  |  read more...
USD 990
2014 Strategies for the German Respiratory Diseases Diagnostic Testing Market
1/29/2014 | published by: VPGMarketResearch.com
... supplier shares for Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV and Tuberculosis. The report provides test volume and sales projections for Hospitals and Commercial/Private Labs. In addition to market share and sales forecasts, the report: ...  |  read more...
USD 1,950
2014 Strategies for the Japanese Respiratory Diseases Diagnostic Testing Market
1/29/2014 | published by: VPGMarketResearch.com
... supplier shares for Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV and Tuberculosis. The report provides test volume and sales projections for Hospitals and Commercial/Private Labs. In addition to market share and sales forecasts, the report: ...  |  read more...
USD 2,400
2014 Strategies for the Spanish Respiratory Diseases Diagnostic Testing Market
1/29/2014 | published by: VPGMarketResearch.com
... supplier shares for Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV and Tuberculosis. The report provides test volume and sales projections for Hospitals and Commercial/Private Labs. In addition to market share and sales forecasts, the report: ...  |  read more...
USD 1,950
2014 Strategies for the UK Respiratory Diseases Diagnostic Testing Market
1/29/2014 | published by: VPGMarketResearch.com
... supplier shares for Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV and Tuberculosis. The report provides test volume and sales projections for Hospitals, Commercial and Public Health Labs. In addition to market share and sales forecasts, ...  |  read more...
USD 1,950
2014 Strategies for the US Respiratory Diseases Diagnostic Testing Market
1/29/2014 | published by: VPGMarketResearch.com
... supplier shares for Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV and Tuberculosis. The report provides test volume and sales projections for Hospitals, Physician Offices, Commercial, and Public Health Labs. In addition to market share and ...  |  read more...
USD 3,600
2014 Analysis of Respiratory Diseases in France: Market Outlook and Emerging Opportunities
11/25/2013 | published by: VPGMarketResearch.com
... forecasts and supplier shares for Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV and Tuberculosis.  The report provides test volume and sales projections for Hospitals and Commercial/Private Labs.  In addition to market share and sales forecasts, ...  |  read more...
USD 1,950
Pulmonary Inflammation - Pipeline Review, H1 2014
5/21/2014 | published by: Global Markets Direct
... therapeutic development for Pulmonary Inflammation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ...  |  read more...
USD 2,000
Pharmaceuticals: Pulmonary Drug Delivery Systems: Technologies and Global Markets
5/1/2014 | published by: BCC Research
... with a compound annual growth rate (CAGR) of 6.2%. This report provides: A detailed overview and thorough analysis of the present and future global markets for pulmonary drug delivery technologies Analyses of global market trends, ...  |  read more...
USD 6,650
Update: Idiopathic Pulmonary Fibrosis Pipeline Highlights – 2014
5/1/2014 | published by: Fore Pharma
... It covers emerging therapies for Idiopathic Pulmonary Fibrosis in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating ...  |  read more...
USD 590
Market Highlights: Spain Bronchitis – 2014
5/1/2014 | published by: Fore Pharma
... market size estimates for 2013, market share forecast for six years to 2019, bronchitis drugs market share, bronchitis drugs sales estimates, bronchitis drugs sales forecast, and bronchitis late stage pipeline products.This research helps executives track ...  |  read more...
USD 990
2014 Opportunities in the French Respiratory Diseases Diagnostic Testing Market
12/6/2013 | published by: VPGMarketResearch.com
... supplier shares for Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV and Tuberculosis.  The report provides test volume and sales projections for Hospitals and Commercial/Private Labs.  In addition to market share and sales forecasts, the report: ...  |  read more...
USD 1,950
Market Highlights: UK Bronchitis – 2014
5/1/2014 | published by: Fore Pharma
... market size estimates for 2013, market share forecast for six years to 2019, bronchitis drugs market share, bronchitis drugs sales estimates, bronchitis drugs sales forecast, and bronchitis late stage pipeline products.This research helps executives track ...  |  read more...
USD 990
2014 Analysis of Respiratory Diseases in Germany: Market Outlook and Emerging Opportunities
11/25/2013 | published by: VPGMarketResearch.com
... forecasts and supplier shares for Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV and Tuberculosis.  The report provides test volume and sales projections for Hospitals and Commercial/Private Labs.  In addition to market share and sales forecasts, ...  |  read more...
USD 1,950
2014 Opportunities in the German Respiratory Diseases Diagnostic Testing Market
12/6/2013 | published by: VPGMarketResearch.com
... supplier shares for Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV and Tuberculosis.  The report provides test volume and sales projections for Hospitals and Commercial/Private Labs.  In addition to market share and sales forecasts, the report: ...  |  read more...
USD 1,950
2014 Analysis of Respiratory Diseases in Spain: Market Outlook and Emerging Opportunities
11/25/2013 | published by: VPGMarketResearch.com
... forecasts and supplier shares for Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV and Tuberculosis.  The report provides test volume and sales projections for Hospitals and Commercial/Private Labs.     In addition to market share and sales forecasts, ...  |  read more...
USD 1,950
Chronic Obstructive Pulmonary Disorder (COPD) - KOL Insight and Consensus Outlook
1/20/2014 | published by: FirstWord
... a 5 year CAGR of 7.1% this high growth sector is set for radical change as new products and combinations are introduced changing both the treatment and competitive landscapes. The cosy carve up of the ...  |  read more...
USD 7,495
1    3    5  6  7  8  9  10